Related references
Note: Only part of the references are listed.Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus
Brian J. Werth et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections
Pier Giorgio Cojutti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Antibacterial Resistance Leadership Group 2.0: Back to Business
Henry F. Chambers et al.
CLINICAL INFECTIOUS DISEASES (2021)
Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review
Morgan Matt et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Synergy Between Beta-Lactams and Lipo-, Glyco-, and Lipoglycopeptides, Is Independent of the Seesaw Effect in Methicillin-Resistant Staphylococcus aureus
Rutan Zhang et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
Luis Buzon-Martin et al.
ANTIBIOTICS-BASEL (2021)
Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels
Kelly M. Hines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells
Vladimir Vimberg et al.
FRONTIERS IN MICROBIOLOGY (2020)
Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights
Razieh Kebriaei et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections
Michael P. Veve et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
Jacinda C. Abdul-Mutakabbir et al.
ANTIBIOTICS-BASEL (2020)
Effect of tolerance on the evolution of antibiotic resistance under drug combinations
Jiafeng Liu et al.
SCIENCE (2020)
Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience
Lauren E. Brownell et al.
DRUGS-REAL WORLD OUTCOMES (2020)
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Nicholas W. Van Hise et al.
DRUGS-REAL WORLD OUTCOMES (2020)
Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection
Sarah B. Doernberg et al.
CLINICAL INFECTIOUS DISEASES (2019)
Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus
Xhilda Xhemali et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
Kasper Iversen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections
L. Morata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci
T. Wu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Oral versus Intravenous Antibiotics for Bone and Joint Infection
H. -K. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
Chloe Bryson-Cahn et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Multicenter clinical experience of real life Dalbavancin use in gram-positive infections
S. Wunsch et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin
Samira Dahesh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection
Selma Tobudic et al.
INFECTION (2019)
French national cohort of first use of dalbavancin: A high proportion of off-label use
Aurelien Dinh et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report
Martina Spaziante et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Carmen Hidalgo-Tenorio et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2019)
Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays
Angela Kavanagh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
Mark Redell et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility
Thamer A. Almangour et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review
Daniel B. Chastain et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
Urania Rappo et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
Jacqueline T. Bork et al.
INFECTIOUS DISEASES AND THERAPY (2019)
Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections
Lucas T. Schulz et al.
PHARMACOTHERAPY (2018)
Examination of the Clostridioides (Clostridium) difficile VanZ ortholog, CD1240
Emily C. Woods et al.
ANAEROBE (2018)
Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays
Qun Yan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna
Selma Tobudic et al.
CLINICAL INFECTIOUS DISEASES (2018)
Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen
B. J. Werth et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
M. A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Dalbavancin in the treatment of different gram-positive infections: a real-life experience
Emilio Bouza et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases
Rupak Datta et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Oritavancin for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci Osteomyelitis
Rachel A. Foster et al.
INFECTIOUS DISEASES IN CLINICAL PRACTICE (2018)
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci
Debora Sweeney et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In-vitro activity of ceftriaxone combined with newer agents against MRSA
Gulseren Aktas
JOURNAL OF CHEMOTHERAPY (2017)
Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin
Dino J. Delaportas et al.
PHARMACOTHERAPY (2017)
Antibiotic tolerance facilitates the evolution of resistance
Irit Levin-Reisman et al.
SCIENCE (2017)
Streptococcus suis serotype 9 strain GZ0565 contains a type VII secretion system putative substrate EsxA that contributes to bacterial virulence and a vanZ-like gene that confers resistance to teicoplanin and dalbavancin in Streptococcus agalactiae
Liying Lai et al.
VETERINARY MICROBIOLOGY (2017)
Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci
Francis F. Arhin et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2017)
Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections
Francis F. Arhin et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2017)
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)
Michael A. Pfaller et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2017)
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci
Francis F. Arhin et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
Cassie L. Stewart et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility
Ronald N. Jones et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci
Jordan R. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team
Charles Knirsch et al.
CLINICAL INFECTIOUS DISEASES (2016)
Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)
Ronald N. Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2016)
Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring
Nobuyuki Ashizawa et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2016)
Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance
Daina Zeng et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
Karrine D. Brade et al.
INFECTIOUS DISEASES AND THERAPY (2016)
Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials
C. M. Rubino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide
Ronald N. Jones et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue
Michael W. Dunne et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Oritavancin: A Long-Half-Life Lipoglycopeptide
Louis D. Saravolatz et al.
CLINICAL INFECTIOUS DISEASES (2015)
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Scott R. Evans et al.
CLINICAL INFECTIOUS DISEASES (2015)
Surrogate analysis of vancomycin to of predict susceptible categorization of dalbavancin
Ronald N. Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review
Francoise Van Bambeke
DRUGS (2015)
Dalbavancin for the treatment of acute bacterial skin and skin structure infections
Sheena Ramdeen et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
Michael W. Dunne et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2015)
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Laura M. Koeth et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
Prolonged use of oritavancin for vancomycin-resistantEnterococcus faeciumprosthetic valve endocarditis
Jennifer A. Johnson et al.
Open Forum Infectious Diseases (2015)
Defining Daptomycin Resistance Prevention Exposures in Vancomycin-Resistant Enterococcus faecium and E-faecalis
B. J. Werth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Antistaphylococcal Activity of Oritavancin and Its Synergistic Effect in Combination with Other Antimicrobial Agents
Gengrong Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection
Anthony M. Casapao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model
Daniela Baldoni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
Francis F. Arhin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations
Hoang Anh Nguyen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
VanA-Type Vancomycin-Resistant Staphylococcus aureus
Bruno Perichon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains
Hoang Anh Nguyen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach
Joseph M. Blondeau
VETERINARY DERMATOLOGY (2009)
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: Implications for susceptibility testing
Francis F. Arhin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
Francis F. Arhin et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections
Andrew M. Roecker et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent
Robert P. Rennie et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Mutant selection window hypothesis updated
Karl Drlica et al.
CLINICAL INFECTIOUS DISEASES (2007)
Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms
Thomas R. Fritsche et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Selection of a surrogate agent (Vancomycin or Teicoplanin) for initial susceptibility testing of dalbavancin: Results from an international antimicrobial surveillance program
Ronald N. Jones et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions
David M. Johnson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
SM Bhavnani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens
I Raad et al.
CLINICAL INFECTIOUS DISEASES (2005)
Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide
RN Jones et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene
S Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis
A Lefort et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
JR Aeschlimann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
